The relationship of serum visfatin levels with clinical parameters, flow-mediated dilation, and carotid intima-media thickness in patients with ankylosing spondylitis

被引:7
作者
Aydogan Baykara, Rabia [1 ]
Kucuk, Adem [2 ]
Tuzcu, Ayca [3 ]
Tuzcu, Goksel [4 ]
Cure, Erkan [5 ]
Uslu, Ali Ugur [6 ]
Omma, Ahmet [7 ]
机构
[1] Turgut Ozal Univ, Malatya Training & Res Hosp, Dept Phys Med & Rehabil, Malatya, Turkey
[2] Necmettin Erbakan Univ, Fac Med, Dept Rheumatol, Konya, Turkey
[3] Adnan Menderes Univ, Fac Med, Dept Biochem, Aydin, Turkey
[4] Aydin Ataturk State Hosp, Dept Radiol, Aydin, Turkey
[5] Ota & Jinemed Hosp, Dept Internal Med, Istanbul, Turkey
[6] Yunus Emre State Hosp, Dept Internal Med, Eskisehir, Turkey
[7] Ankara Numune Training & Res Hosp, Dept Rheumatol, Ankara, Turkey
关键词
Visfatin; ankylosing spondylitis; flow-mediated dilation; carotid intima-media thickness; subclinical atherosclerosis; ENDOTHELIAL DYSFUNCTION; SUBCLINICAL ATHEROSCLEROSIS; METABOLIC SYNDROME; RISK-FACTORS; DISEASE; PREVALENCE; PLASMA;
D O I
10.3906/sag-2012-351
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/aim: Atherosclerotic heart diseases can occur at an early age in patients with ankylosing spondylitis (AS). Flow-mediated dilation (FMD) and carotid intima-media thickness (cIMT) values are reliable markers for early detection of subclinical atherosclerosis in patients with AS. We aimed to investigate the relationship between visfatin levels and indirect markers of subclinical atherosclerosis and endothelial dysfunction in patients with AS. Materials and methods: Forty-two patients diagnosed with AS and 42 age, sex, and body mass index (BMI)-matched controls were included in the study. Visfatin levels, FMD, and cIMT were measured using appropriate methods. Results: Visfatin levels of the patients were significantly higher than controls (p < 0.001). FMD values in patients with AS were significantly lower (p = 0.007) whereas cIMT were significantly higher than the controls (p = 0.003). There was a negative relationship between FMD with visfatin levels (p = 0.004), BASDAI (p = 0.010), and BASFI (p = 0.007). There was a positive relationship between cIMT with visfatin (p = 0.005), BASDAI (p < 0.001), and BASFI (p < 0.001). There was a positive relationship between visfatin with BASDAI (p < 0.001), and BASFI (p < 0.001). Conclusion: Visfatin levels are increased and associated with impaired FMD and increased cIMT in patients with AS. Increased visfatin levels may be associated with subclinical atherosclerosis in AS.
引用
收藏
页码:1865 / 1874
页数:10
相关论文
共 40 条
[1]   Measurement of endothelial function and its clinical utility for cardiovascular risk [J].
Al-Qaisi, Mo ;
Kharbanda, Rajesh K. ;
Mittal, Tarun K. ;
Donald, Ann E. .
VASCULAR HEALTH AND RISK MANAGEMENT, 2008, 4 (03) :647-652
[2]  
Balciunaite A., 2020, CASE REP RHEUMATOL, V2020, P9538527, DOI [10.1155/2020/9538527, DOI 10.1155/2020/9538527]
[3]   Serum visfatin as a non-traditional biomarker of endothelial dysfunction in chronic kidney disease: An Egyptian study [J].
Bessa, Sahar S. ;
Hamdy, Soha M. ;
El-Sheikh, Raghda G. .
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2010, 21 (06) :530-535
[4]   Assessment of Subclinical Vascular Disease Associated with Ankylosing Spondylitis [J].
Bodnar, Nora ;
Kerekes, Gyoergy ;
Seres, Ildiko ;
Paragh, Gyoergy ;
Kappelmayer, Janos ;
Nemethne, Zsuzsanna Gyurcsik ;
Szegedi, Gyula ;
Shoenfeld, Yehuda ;
Sipka, Sandor ;
Soltesz, Pal ;
Szekanecz, Zoltan ;
Szanto, Sandor .
JOURNAL OF RHEUMATOLOGY, 2011, 38 (04) :723-729
[5]  
Cakmak HA, 2015, HERZ, V40, P921, DOI 10.1007/s00059-015-4313-4
[6]   Atherogenic index of plasma: a useful marker for subclinical atherosclerosis in ankylosing spondylitis [J].
Cure, Erkan ;
Icli, Abdullah ;
Uslu, Ali Ugur ;
Sakiz, Davut ;
Cure, Medine Cumhur ;
Baykara, Rabia Aydogan ;
Yavuz, Fatma ;
Arslan, Sevket ;
Kucuk, Adem .
CLINICAL RHEUMATOLOGY, 2018, 37 (05) :1273-1280
[7]  
El-Shishtawy Samia Hassan, 2016, Electron Physician, V8, P1966, DOI 10.19082/1966
[8]   Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis? [J].
Eriksson, Jonas K. ;
Jacobsson, Lennart ;
Bengtsson, Karin ;
Askling, Johan .
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (02) :364-370
[9]   Visfatin/PBEF and Atherosclerosis-Related Diseases [J].
Filippatos, Theodosios D. ;
Randeva, Harpal S. ;
Derdemezis, Christos S. ;
Elisaf, Moses S. ;
Mikhailidis, Dimitri P. .
CURRENT VASCULAR PHARMACOLOGY, 2010, 8 (01) :12-28
[10]   Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease [J].
Genc, Halit ;
Dogru, Teoman ;
Kara, Muammer ;
Tapan, Serkan ;
Ercin, Cemal Nuri ;
Acikel, Cengizhan ;
Karstioglu, Yildirim ;
Bagci, Sait .
ANNALS OF HEPATOLOGY, 2013, 12 (04) :380-387